October 27, 2026

AdipoPharma Advances PATAS into Phase 1b Clinical Trial in Patients with Type 2 Diabetes

First participants with Type 2 diabetes dosed in multiple ascending dose (MAD) study evaluating AdipoPharma’s first-in-class insulin sensitizer Advancement follows successful completion of the single ascending dose (SAD) phase, where PATAS was well tolerated with no serious adverse events STRASBOURG, France, Oct. 27, 2026 (GLOBE NEWSWIRE) — AdipoPharma, a clinical-stage biotechnology company developing therapies that […]

Read More . .

JETOUR Showcases Future Mobility Technologies, Deepening Its Global “Travel+” Strategy

JETOUR G700 Showcases SOLAIR Technology at the 2026 Global Technology Experience Day JETOUR G700 with SOLAIR technology for off-road travel. WUHU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) — Advances in artificial intelligence and new energy technologies are expanding what vehicles can do. Ke Chuandeng, President of JETOUR’s International, said: “The future evolution of vehicles lies […]

Read More . .